Clinicopathological Features of Anticancer Drug-induced Kidney Injury

doi:10.12114/j.issn.1007-9572.2022.0372

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (33): 4153-4158.DOI: 10.12114/j.issn.1007-9572.2022.0372

Special Issue: 肿瘤最新文章合辑；泌尿系统疾病最新文章合辑

• Article • Previous Articles Next Articles

Clinicopathological Features of Anticancer Drug-induced Kidney Injury

Hebei Clinical Research Center for Chronic Kidney Disease/Hebei Key Laboratory of Vascular Calcification in Kidney Disease/Department of Nephrology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, China

Received:2022-03-19 Revised:2022-08-06 Published:2022-11-20 Online:2022-09-01
Contact: XU Jinsheng
About author:
GENG T H, LI H, JIN J J, et al. Clinicopathological features of anticancer drug-induced kidney injury[J]. Chinese General Practice, 2022, 25 (33) : 4153-4158, 4167.

抗肿瘤药物相关肾损害患者的临床病理特点分析

050011　河北省石家庄市，河北省慢性肾病临床医学研究中心　河北省肾脏病血管钙化重点实验室　河北医科大学第四医院肾内科

通讯作者: 徐金升
作者简介:
耿同会，李涵，靳晶晶，等.抗肿瘤药物相关肾损害患者的临床病理特点分析[J].中国全科医学，2022，25（33）：4153-4158，4167. [www.chinagp.net] 作者贡献：白亚玲、徐金升提出研究思路，设计研究方案，研究命题的提出、设计；耿同会、李涵负责数据收集、整理和统计学分析，图表的绘制，结果的可视化呈现，负责论文起草、初步撰写；靳晶晶、程美娟、张胜雷负责论文审阅、修改；徐金升负责最终版本修订，对论文负责。
基金资助:
河北省医学技术跟踪项目(G2018050); 河北省重点研发计划项目(20377704D); 河北省科技计划项目(16397733D)

Abstract

Abstract:

Background

The prevalence of anticancer drug-induced kidney injury is increasing, but related renal pathology studies are still rare.

Objective

To analyze the clinicopathological characteristics of patients with anticancer drug-related kidney injury.

Methods

We selected 112 cancer inpatients aged 18 years or older with kidney injury (kidney injury occurred after cancer or nearly at the same time as cancer, and may be directly or indirectly associated with anticancer treatment) detected by kidney biopsy from Department of Nephrology, the Fourth Hospital of Hebei Medical University from October 2013 to August 2021. We assigned those (n=65) who were previously treated with chemotherapy, molecularly targeted drugs or immune checkpoint inhibitors and other systemic treatments to an anticancer drug group, and other cases (n=47) to a non-use anticancer drug group. We collected their demographics, laboratory examination and pathological data, and analyzed the clinical features and pathological characteristics of kidney of those with anticancer drug-related kidney injury.

Results

In the anticancer drug group, acute kidney injury (AKI) occurred in 30 (50.8%) out of 59 cases of solid cancer, and in 4 out of 6 cases of hematological cancer. In non-use anticancer drug group, AKI occurred in 11 (31.4%) out of 35 cases of solid cancer, and in 6 (50.0%) out of 12 cases of hematological cancer. The serum creatinine level increased after treatment in the anticancer drug group (P<0.001) . Anticancer drug group and non-use anticancer drug group had significant differences in sex ratio, smoking prevalence, mean serum albumin and elevated urinary protein excretion prevalence (P<0.05) , but had no significant differences in mean age, hemoglobin, serum creatinine, urea nitrogen, uric acid, D-dimer, total cholesterol, triacylglycerol, and 24-hour urinary protein quantification, as well as prevalence of diabetes, hypertension, and AKI (P>0.05) . Solid cancer patients with anticancer drug treatment had higher prevalence of tubulointerstitial injury (P=0.023) and lower prevalence ofmembranous nephrosis (P=0.004) compared with those without anticancer drug treatment. Renal tubulointerstitial injury was the main pathological manifestations in the anticancer drug group〔34 cases (52.3%) 〕. Membranous nephropathy〔18 cases (38.3%) 〕and tubulointerstitial injury〔18 cases (38.3%) 〕were main pathological manifestations in the non-use anticancer drug group.

Conclusion

There are various clinical and pathological types of anticancer drug-induced kidney injury. The application of anticancer drug may cause damage to renal function, so priority should be given to the prevention of renal tubulointerstitial injury during the treatment.

Key words: Neoplasms, Antineoplastic agents, Renal damage, Clinical features, Pathological features, Disease attributes

摘要：

背景

肿瘤治疗措施导致的肾损害日益多见，而该领域关于相应患者肾脏病理的研究较少。

目的

分析抗肿瘤药物相关肾损害患者的临床及肾脏病理特点。

方法

选取2013年10月至2021年8月在河北医科大学第四医院肾内科住院并行肾穿刺活检的≥18岁患者112例，肾损害出现时间位于发现肿瘤后或者与肿瘤同一时间出现，肾损害与恶性肿瘤或者肿瘤相关治疗存在直接或间接关系；既往应用化疗、分子靶向药物或免疫检查点抑制剂等全身治疗的患者纳入抗肿瘤药物组（65例），其余患者纳入未用抗肿瘤药物组（47例）。收集患者的一般资料、实验室检查和病理资料。分析抗肿瘤药物相关肾损害患者的临床及肾脏病理特点。

结果

抗肿瘤药物组中59例实体瘤患者发生急性肾损伤（AKI）30例（50.8%），6例血液系统肿瘤患者发生AKI 4例（4/6）。未用抗肿瘤药物组35例实体瘤患者中发生AKI 11例（31.4%），12例血液系统肿瘤患者发生AKI 6例（50.0%）。抗肿瘤药物组治疗前血肌酐低于治疗后（P<0.001）。抗肿瘤药物组性别、吸烟比例、血清白蛋白、尿蛋白阳性率与未用抗肿瘤药物组比较，差异有统计学意义（P<0.05）；两组年龄、血红蛋白、血肌酐、尿素氮、尿酸、D-二聚体、糖尿病比例、高血压比例、总胆固醇、三酰甘油、尿蛋白定量、AKI发生率比较，差异无统计学意义（P>0.05）。抗肿瘤药物组实体瘤患者肾脏病理表现为肾小管间质损伤的比例高于未用抗肿瘤药物组（P=0.023），而膜性肾病的比例较未用抗肿瘤药物组低（P=0.004）。抗肿瘤药物组最主要的病理表现为肾小管间质损伤34例（52.3%），未用抗肿瘤药物组最主要的病理表现为膜性肾病18例（38.3%）、肾小管间质损伤18例（38.3%）。

结论

抗肿瘤药物相关肾损害患者的临床及病理存在多种类型，抗肿瘤药物可能会导致肾功能的损害，应用期间应警惕肾小管间质损伤。

关键词: 肿瘤, 抗肿瘤药, 肾损害, 临床特点, 病理特点, 疾病特征

GENG Tonghui,LI Han,JIN Jingjing, et al. Clinicopathological Features of Anticancer Drug-induced Kidney Injury[J]. Chinese General Practice, 2022, 25(33): 4153-4158. DOI: 10.12114/j.issn.1007-9572.2022.0372.
耿同会,李涵,靳晶晶等. 抗肿瘤药物相关肾损害患者的临床病理特点分析[J]. 中国全科医学, 2022, 25(33): 4153-4158. DOI: 10.12114/j.issn.1007-9572.2022.0372.

Figures/Tables 5

References 30

[1]	BRAY F, FERLAY J, SOERJOMATARAM I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2018，68(6):394-424. DOI：10.3322/caac.21492.
[2]	曹毛毛，陈万青. 中国恶性肿瘤流行情况及防控现状[J]. 中国肿瘤临床，2019，46(3):145-149. DOI：10.3969/j.issn.1000-8179.2019.03.246.
[3]	KITAI Y, MATSUBARA T, YANAGITA M. Onco-nephrology：current concepts and future perspectives[J]. Jpn J Clin Oncol，2015，45(7):617-628. DOI：10.1093/jjco/hyv035.
[4]	ROSNER M H, JHAVERI K D, MCMAHON B A，et al. Onconephrology：The intersections between the kidney and cancer[J]. CA Cancer J Clin，2021，71(1):47-77. DOI：10.3322/caac.21636.
[5]	CHANG F C, CHEN T W W, HUANG T T M，et al. Spectrum of cancer patients receiving renal biopsy[J]. J Formos Med Assoc，2022，121(1 Pt 1):152-161. DOI：10.1016/j.jfma.2021.02.009.
[6]	庄永泽. 肿瘤相关性急性肾损伤的研究进展[J]. 中华肾病研究电子杂志，2019，8(4):150-154. DOI：10.3877/cma.j.issn.2095-3216.2019.04.002.
[7]	CAPASSO A, BENIGNI A, CAPITANIO U，et al. Summary of the International Conference on Onco-Nephrology：an emerging field in medicine[J]. Kidney Int，2019，96(3):555-567. DOI：10.1016/j.kint.2019.04.043.
[8]	SANTOS M L C, DE BRITO B B, DA SILVA F A F，et al. Nephrotoxicity in cancer treatment：an overview[J]. World J Clin Oncol，2020，11(4):190-204. DOI：10.5306/wjco.v11.i4.190.
[9]	PISCITANI L, SIROLLI V, DI LIBERATO L，et al. Nephrotoxicity associated with novel anticancer agents （aflibercept，dasatinib，nivolumab）：case series and nephrological considerations[J]. Int J Mol Sci，2020，21(14):E4878. DOI：10.3390/ijms21144878.
[10]	ZHANG D, ZHANG C, BIAN F，et al. Clinicopathological features in membranous nephropathy with cancer：a retrospective single-center study and literature review[J]. Int J Biol Markers，2019，34(4):406-413. DOI：10.1177/1724600819882698.
[11]	ZHANG D, ZHANG C, BIAN F，et al. Clinicopathological features in membranous nephropathy with cancer：a retrospective single-center study and literature review[J]. Int J Biol Markers，2019，34(4):406-413. DOI：10.1177/1724600819882698.
[12]	石朋先，任贵生，胡伟新. 抗肿瘤药物相关肾损伤的研究进展[J]. 医学研究生学报，2019，32(6):652-656. DOI：10.16571/j.cnki.1008-8199.2019.06.019.
[13]	CORTAZAR F B, MARRONE K A, TROXELL M L，et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors[J]. Kidney Int，2016，90(3):638-647. DOI：10.1016/j.kint.2016.04.008.
[14]	SHIRALI A C, PERAZELLA M A, GETTINGER S. Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients[J]. Am J Kidney Dis，2016，68(2):287-291. DOI：10.1053/j.ajkd.2016.02.057.
[15]	CHEN M J, ZHANG L, ZHONG W，et al. Case report：THSD7A-positive membranous nephropathy caused by tislelizumab in a lung cancer patient[J]. Front Immunol，2021，12:619147. DOI：10.3389/fimmu.2021.619147.
[16]	LIN J S, WANG D Y, MAMLOUK O，et al. Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab[J]. J Immunother Cancer，2020，8(2):e001287. DOI：10.1136/jitc-2020-001287.
[17]	CAZA T N, HASSEN S I, DVANAJSCAK Z，et al. NELL1 is a target antigen in malignancy-associated membranous nephropathy[J]. Kidney Int，2021，99(4):967-976. DOI：10.1016/j.kint.2020.07.039.
[18]	MARTÍNEZ-VALENZUELA L, DRAIBE J, FULLADOSA X，et al. Acute tubulointerstitial nephritis in clinical oncology：a comprehensive review[J]. Int J Mol Sci，2021，22(5):2326. DOI：10.3390/ijms22052326.
[19]	BIRO E, SZIKSZAY E, PETHO-OROSZ P，et al. Acute interstitial nephritis in T-cell leukemia in a pediatric patient[J]. Pediatr Int，2016，58(9):940-942. DOI：10.1111/ped.13029.
[20]	HEGGERMONT W A, VERHOEF G, EVENEPOEL P，et al. Clinical case report：a rare cause of acute kidney failure - tissue is the issue[J]. Acta Clin Belg，2017，72(3):201-204. DOI：10.1080/17843286.2016.1178967.
[21]	YACOUB G, KOSSEIFI S G, SHAH L S，et al. IgA nephropathy and small cell lung carcinoma[J]. Tenn Med，2008，101(3):35-37,40.
[22]	MIMURA I, TOJO A, KINUGASA S，et al. Renal cell carcinoma in association with IgA nephropathy in the elderly[J]. Am J Med Sci，2009，338(5):431-432. DOI：10.1097/MAJ.0b013e3181ae1b12.
[23]	BERGMANN J, BUCHHEIDT D, WALDHERR R，et al. IgA nephropathy and Hodgkin's disease：a rare coincidence. Case report and literature review[J]. Am J Kidney Dis，2005，45(1):e16-19. DOI：10.1053/j.ajkd.2004.09.007.
[24]	HOMMEL C, RIHOVA Z, MOKADDEM F，et al. PANCA-vasculitis associated with rectal adenocarcinoma[J]. Acta Clin Belg，2014，69(6):463-466. DOI：10.1179/2295333714Y.0000000064.
[25]	LI X X, HUANG M C, LIU J. ANCA-associated vasculitis with anti-GBM disease and two types of tumors：a case report[J]. Front Med （Lausanne），2022，8:810680. DOI：10.3389/fmed.2021.810680.
[26]	JHAVERI K D, SHAH H H, CALDERON K，et al. Glomerular diseases seen with cancer and chemotherapy：a narrative review[J]. Kidney Int，2013，84(1):34-44. DOI：10.1038/ki.2012.484.
[27]	LIU K, QIN Z K, XU X Q，et al. Comparative risk of renal adverse events in patients receiving immune checkpoint inhibitors：a Bayesian network meta-analysis[J]. Front Oncol，2021，11:662731. DOI：10.3389/fonc.2021.662731.
[28]	KANG E, PARK M, PARK P G，et al. Acute kidney injury predicts all-cause mortality in patients with cancer[J]. Cancer Med，2019，8(6):2740-2750. DOI：10.1002/cam4.2140.
[29]	陈浩，曾彩虹. 套细胞淋巴瘤导致的肾损害[J]. 肾脏病与透析肾移植杂志，2014，23(4):390-394.
[30]	翟子涵，房豫东，苟蓉，等. 女性套细胞淋巴瘤肾损害一例[J]. 中华肾脏病杂志，2016，32(3):225-226. DOI：10.3760/cma.j.issn.1001-7097.2016.03.011.

组别	例数	性别（男/女）	年龄（±s，岁）	吸烟〔n（%）〕	血红蛋白（g/L）	血清白蛋白（±s，g/L）	血肌酐〔M（QR），μmol/L〕	尿素氮〔M（QR），mg/dl〕	尿酸〔M（QR），μmol/L〕
抗肿瘤药物组	65	38/27	58.9±10.2	20（30.8）	106.0（29.3）	32.9±7.8	128.7（161.1）	8.1（8.0）	390.3（169.2）
未用抗肿瘤药物组	47	10/37	59.3±11.8	29（61.7）	109.4±27.1	29.6±9.5	105.0（187.6）	8.8（8.9）	395.4（158.5）
检验统计量值		5.062^a	0.249^b	10.606^a	-0.233^c	-2.120^b	-0.315^c	-0.399^c	-1.275^c
P值		0.024	0.862	0.001	0.816	0.034	0.752	0.690	0.202
组别	D-二聚体〔M（QR），ng〕	糖尿病〔n（%）〕	高血压〔n（%）〕	总胆固醇〔M（QR），mmol/L〕	三酰甘油〔M（QR），mmol/L〕	尿蛋白阳性〔n（%）〕	尿蛋白定量〔M（QR），mg/24 h〕	急性肾损伤〔n（%）〕
抗肿瘤药物组	0.54（1.32）	9（13.8）	35（53.8）	1.75（1.49）	4.81（2.08）	43（66.2）	2 616（3 879）	34（52.3）
未用抗肿瘤药物组	0.81（1.36）	6（12.8）	25（53.2）	1.68（1.11）	5.40（3.72）	42（89.4）	4 117（6 755）	17（36.2）
检验统计量值	-0.960^c	0.027^a	0.005^a	-0.131^c	-0.497^c	8.030^a	-1.599^c	2.864^a
P值	0.337	0.868	0.945	0.896	0.619	0.005	0.066	0.091

组别	例数	性别（男/女）	年龄（±s，岁）	吸烟〔n（%）〕	血红蛋白（g/L）	血清白蛋白（±s，g/L）	血肌酐〔M（QR），μmol/L〕	尿素氮〔M（QR），mg/dl〕	尿酸〔M（QR），μmol/L〕
抗肿瘤药物组	65	38/27	58.9±10.2	20（30.8）	106.0（29.3）	32.9±7.8	128.7（161.1）	8.1（8.0）	390.3（169.2）
未用抗肿瘤药物组	47	10/37	59.3±11.8	29（61.7）	109.4±27.1	29.6±9.5	105.0（187.6）	8.8（8.9）	395.4（158.5）
检验统计量值		5.062^a	0.249^b	10.606^a	-0.233^c	-2.120^b	-0.315^c	-0.399^c	-1.275^c
P值		0.024	0.862	0.001	0.816	0.034	0.752	0.690	0.202
组别	D-二聚体〔M（QR），ng〕	糖尿病〔n（%）〕	高血压〔n（%）〕	总胆固醇〔M（QR），mmol/L〕	三酰甘油〔M（QR），mmol/L〕	尿蛋白阳性〔n（%）〕	尿蛋白定量〔M（QR），mg/24 h〕	急性肾损伤〔n（%）〕
抗肿瘤药物组	0.54（1.32）	9（13.8）	35（53.8）	1.75（1.49）	4.81（2.08）	43（66.2）	2 616（3 879）	34（52.3）
未用抗肿瘤药物组	0.81（1.36）	6（12.8）	25（53.2）	1.68（1.11）	5.40（3.72）	42（89.4）	4 117（6 755）	17（36.2）
检验统计量值	-0.960^c	0.027^a	0.005^a	-0.131^c	-0.497^c	8.030^a	-1.599^c	2.864^a
P值	0.337	0.868	0.945	0.896	0.619	0.005	0.066	0.091

抗肿瘤药物组	例数	未用抗肿瘤药物组	例数
肾小管间质损伤	19	膜性肾病	16
膜性肾病	11	肾小管间质损伤	8
IgA肾病	7	IgA肾病	5
局灶节段性肾小球硬化症伴肾小管间质损伤	5	管型肾病伴肾小管间质损伤	3
管型肾病伴肾小管间质损伤	3	缺血性肾损伤	3
缺血性肾病伴肾小管间质损伤	2	膜性肾病伴肾小管间质损伤	2
IgA肾病伴缺血性肾损伤	2	IgA肾病伴肾小管间质损伤	2
缺血性肾损伤	2	局灶节段性肾小球硬化症	1
IgA肾病伴肾小管间质损伤	2	抗中性粒细胞胞浆抗体相关小血管炎肾损害	1
系膜增生性肾小球病	2	系膜增生性肾小球病	1
肾淀粉样变性伴管型肾病	2	肾淀粉样变性伴肾小管间质损伤	1
系膜增生性肾小球病伴肾小管间质损伤	1	肾淀粉样变性	1
毛细血管内皮细胞病	1	管型肾病	1
血栓性微血管病	1	系膜增生性肾小球病伴肾小管间质损伤	1
肾小球微小病变	1	局灶节段性肾小球硬化症伴肾小管间质损伤	1
肾淀粉样变性	1
局灶节段性肾小球硬化症	1
膜性肾病伴肾小管间质损伤	1
足细胞病伴肾小管间质损伤	1

抗肿瘤药物组	例数	未用抗肿瘤药物组	例数
肾小管间质损伤	19	膜性肾病	16
膜性肾病	11	肾小管间质损伤	8
IgA肾病	7	IgA肾病	5
局灶节段性肾小球硬化症伴肾小管间质损伤	5	管型肾病伴肾小管间质损伤	3
管型肾病伴肾小管间质损伤	3	缺血性肾损伤	3
缺血性肾病伴肾小管间质损伤	2	膜性肾病伴肾小管间质损伤	2
IgA肾病伴缺血性肾损伤	2	IgA肾病伴肾小管间质损伤	2
缺血性肾损伤	2	局灶节段性肾小球硬化症	1
IgA肾病伴肾小管间质损伤	2	抗中性粒细胞胞浆抗体相关小血管炎肾损害	1
系膜增生性肾小球病	2	系膜增生性肾小球病	1
肾淀粉样变性伴管型肾病	2	肾淀粉样变性伴肾小管间质损伤	1
系膜增生性肾小球病伴肾小管间质损伤	1	肾淀粉样变性	1
毛细血管内皮细胞病	1	管型肾病	1
血栓性微血管病	1	系膜增生性肾小球病伴肾小管间质损伤	1
肾小球微小病变	1	局灶节段性肾小球硬化症伴肾小管间质损伤	1
肾淀粉样变性	1
局灶节段性肾小球硬化症	1
膜性肾病伴肾小管间质损伤	1
足细胞病伴肾小管间质损伤	1

化疗	例数	分子靶向药物	例数	免疫治疗	例数
肾小管间质损伤	13	肾小管间质损伤	5	肾小管间质损伤	3
膜性肾病	10	缺血性肾损伤伴肾小管间质损伤	2	IgA肾病	3
局灶节段性肾小球硬化症伴肾小管间质损伤	5	肾小球微小病变	1	膜性肾病伴肾小管间质损伤	1
IgA肾病	3	系膜增生性肾小球病	1	系膜增生性肾小球病伴肾小管间质损伤	1
缺血性肾损伤	2	IgA肾病	1
管型肾病伴肾小管间质损伤	2	IgA肾病伴缺血性肾损伤	1
IgA肾病伴肾小管间质损伤	1	IgA肾病伴肾小管间质损伤	1
系膜增生性肾小球病	1	局灶节段性肾小球硬化症	1
血栓性微血管病	1	足细胞病伴肾小管间质损伤	1
管型肾病	1
IgA肾病伴缺血性肾损伤	1
肾淀粉样变伴管型肾病	1
肾淀粉样变	1
毛细血管内皮细胞病	1

Clinicopathological Features of Anticancer Drug-induced Kidney Injury

抗肿瘤药物相关肾损害患者的临床病理特点分析

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 5

References 30

Related Articles 15

Recommended Articles

Metrics

Comments

组别	例数	膜性肾病	肾小管间质损伤	IgA肾病
抗肿瘤药物组	59	12（20.3）	31（52.5）	11（18.6）
未用抗肿瘤药物组	35	17（48.6）	10（28.6）	6（17.1）
χ²值		8.509	5.133	0.033
P值		0.004	0.023	0.855

变量	β	SE	Wald χ²值	P值	OR（95%CI）
吸烟	0.658	0.414	2.528	0.112	1.930（0.858，4.343）
性别	-0.791	0.423	3.507	0.061	0.453（0.198，1.038）
年龄	0.264	0.336	0.619	0.432	1.302（0.674，2.514）
肿瘤类型	1.451	0.493	8.655	0.003	4.267（1.623，11.220）
治疗措施1	0.244	0.408	0.358	0.550	1.277（0.574，2.841）
治疗措施2	0.835	0.481	3.013	0.083	2.305（0.898，5.918）
治疗措施3	2.266	0.569	15.868	<0.001	9.644（3.162，29.413）

[1]	ZHAO Huili, LU Lina, ZHUO Ya, WANG Xin. Clinical Characteristics and Risk Factors for Recurrence of Cryptogenic Organizing Pneumonia [J]. Chinese General Practice, 2026, 29(19): 2648-2655.
[2]	HE Xiaoming, HE Mincong, WEI Tengfei, LIN Tianye, LIU Wengang, ZHANG Qingwen, HE Wei, WEI Qiushi. Multidimensional Relationship of "TCM Syndrome Type, Clinical Feature and Molecular Typing" in Postmenopausal Patients with Knee Osteoarthritis [J]. Chinese General Practice, 2026, 29(12): 1588-1598.
[3]	XIA Ning, SHI Lan, DING Wanbao, ZHANG Jie, LONG Yi, DAI Hui, ZHANG Can, DAI Hailong. Clinical Characteristics and Prognosis of Patients with Amyloidosis [J]. Chinese General Practice, 2026, 29(09): 1161-1167.
[4]	Chinese Rehabilitation Medicine Association Community Rehabilitation Working Committee. Expert Consensus on Perioperative Nutritional Management for Liver Cancer Based on the Enhanced Recovery after Surgery Concept (2025) [J]. Chinese General Practice, 2026, 29(08): 953-964.
[5]	TIAN Ying, PAN Dianzhu. Analysis of Related Factors of Renal Function Impairment in AECOPD Patients [J]. Chinese General Practice, 2026, 29(07): 885-892.
[6]	YAO Wenjing, WANG Cuifeng, GAO Jinliang, REN Meiying, JING Xuefen, FU Yuhua. Autophagy Related Proteins Beclin-1 and LC3-ⅡExpression in Lung Cancer Metaststic Pleural Effusion [J]. Chinese General Practice, 2026, 29(05): 623-630.
[7]	ZHOU Rui, JIN Yue, LIU Tingting, CAI Kerun, CUI Yiyuan, LI Sicong, LIU Lixing, FENG Li, the Working Group for the Clinical Practice Guideline for the Secondary Bone Malignancy with Integrated Traditional Chinese and Western Medicine. Guidelines for Diagnosis and Treatment of Secondary Malignant Tumors of Bone Combined with Traditional Chinese and Western Medicine [J]. Chinese General Practice, 2026, 29(04): 423-435.
[8]	ZHANG Hui, LUO Miaomiao, YU Xiaohang, LIN Xin, YE Lina, TANG Xuan, LI Jiaxue, XIE Xinyu, LAI Li, FENG Yan, LIU Yonghui, CHEN Weigang. The Application Value of a Novel Cell Collector for the Esophagus in Screening for Esophageal Lesions [J]. Chinese General Practice, 2025, 28(35): 4487-4493.
[9]	LIU Shuyi, LI Yun, YE Peitao, TAN Lunfang, XIE Yanqing, GAO Yi, ZHENG Jinping. Based on Real-world Data Analysis about Clinical Application of Bronchial Provocation Test [J]. Chinese General Practice, 2025, 28(34): 4378-4384.
[10]	Community Rehabilitation Working Committee of Chinese Rehabilitation Medicine Association. Chinese Expert Consensus on Constipation Screening and Assessment for Community Cancer Patients (2025 Edition) [J]. Chinese General Practice, 2025, 28(34): 4249-4257.
[11]	Community Rehabilitation Working Committee of Chinese Rehabilitation Medicine Association. Chinese Expert Consensus on Community-based Cancer-related Fatigue Management (2025 Edition) [J]. Chinese General Practice, 2025, 28(33): 4117-4124.
[12]	ZHANG Jia, WANG Hairong, ZHAO Jing, SU Yifan. Influencing Factors of Screening Behavior of First-degree Relatives of Lung Cancer Patients Based on Logistic Regression and Decision Tree Model [J]. Chinese General Practice, 2025, 28(31): 3961-3967.
[13]	LI Jingling, LIU Ning, GUO Jun. Methodological Quality and Metrological Characteristics of Palliative Care Quality Assessment Tools for Cancer Patients: a Systematic Evaluation Based on COSMIN [J]. Chinese General Practice, 2025, 28(31): 3981-3988.
[14]	XU Baichuan, WANG Yan, ZHANG Peng, LI Yiting, LIU Feilai, XIE Yang. Research and Analysis of Screening Tools for Chronic Obstructive Pulmonary Disease Comorbidity Lung Cancer [J]. Chinese General Practice, 2025, 28(30): 3847-3852.
[15]	HU Jieman, TAN Feixiang, YUAN Anxin, CHEN Shiyu, TANG Chulei, YIN Yueheng, BA Lei, XU Qin. Analysis of the Trajectory of Postoperative Frailty and Influencing Factors in Patients with Colorectal Cancer [J]. Chinese General Practice, 2025, 28(26): 3276-3282.